retatrutide vs UBT251
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1/GIP/glucagon receptor (triple) · full Obesity pipeline
retatrutide
Developed by Eli Lilly
NCT05882045 · Phase 3 · completed
The study was randomized, double-blind, and placebo-controlled, with 1,946 participants enrolled, and its primary endpoint was the clinical obesity outcome of percent change in body weight. The primary comparison favored retatrutide and met its primary endpoint per the sponsor's topline release (no p-value published), but no power calculation or planned enrollment target is provided in the available record, so the evidence is graded moderate rather than strong.
Next expected readout: November 2026 · NCT06662383 (registry estimate)
Reported efficacy
Percent Change from Baseline in Body Weight (Baseline, Week 80); Change from Baseline in Apnea-Hypopnea Index (AHI) for GSA2 Subset (Baseline, Week 80): Primary endpoint, percent change in body weight from baseline to week 80 (treatment-regimen estimand): retatrutide 9 mg -16.8% and 12 mg -18.8% vs placebo -5.1%; treatment differences -11.8% (95% CI -13.7 to -9.8) and -13.8% (95% CI -15.8 to -11.8); p<0.0001 for both, met. Key secondary, 4 mg vs placebo: -11.9% vs -5.1% (difference -6.9%, 95% CI -8.7 to -5.1; p<0.0001). The registered AHI primary in the sleep apnea subset is not reported in the paper abstract. (met)
Result source: NCT05929079
UBT251
Developed by Novo Nordisk under a licence from United Bio-Technology (Hengqin)
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT07785934 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Obesity
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | retatrutide | UBT251 |
|---|---|---|
| Body weight, % change | -17.4% vs -1.6%−15.8 vs placeboNCT0488176014 other results
| —Trial running · NCT07806851 |
| Weight loss of 5% or more | 100% vs 27%+73 vs placeboNCT0488176011 other results
| —Trial running · NCT07806851 |
| Weight loss of 10% or more | 93% vs 9%+84 vs placeboNCT0488176011 other results
| —Trial running · NCT07806851 |
| Waist circumference, change (cm) | -19.6 vs -2.6−17 vs placeboNCT0488176011 other results
| —Trial running · NCT07806851 |
Body weight, % change
- retatrutide
- -17.4% vs -1.6%−15.8 vs placeboNCT04881760
14 other results
- -16.6% vs -1.6% NCT04881760
- -18.3% vs -1.6% NCT04881760
- -12% vs -1.6% NCT04881760
- -13.8% vs -1.6% NCT04881760
- -7.2% vs -1.6% NCT04881760
- -24.2% vs -2.1% NCT04881760
- -21.7% vs -2.1% NCT04881760
- -23.9% vs -2.1% NCT04881760
- -16.3% vs -2.1% NCT04881760
- -17.8% vs -2.1% NCT04881760
- -8.7% vs -2.1% NCT04881760
- -20.8% vs -4% NCT05929079
- -19.1% vs -4% NCT05929079
- -12.7% vs -4% NCT05929079
- UBT251
- —Trial running · NCT07806851
Weight loss of 5% or more
- retatrutide
- 100% vs 27%+73 vs placeboNCT04881760
11 other results
- 97% vs 26% NCT04881760
- 100% vs 27% NCT04881760
- 100% vs 27% NCT04881760
- 100% vs 26% NCT04881760
- 100% vs 26% NCT04881760
- 87% vs 27% NCT04881760
- 97% vs 27% NCT04881760
- 87% vs 26% NCT04881760
- 94% vs 26% NCT04881760
- 64% vs 27% NCT04881760
- 59% vs 26% NCT04881760
- UBT251
- —Trial running · NCT07806851
Weight loss of 10% or more
- retatrutide
- 93% vs 9%+84 vs placeboNCT04881760
11 other results
- 90% vs 3% NCT04881760
- 90% vs 9% NCT04881760
- 91% vs 9% NCT04881760
- 83% vs 3% NCT04881760
- 94% vs 3% NCT04881760
- 73% vs 9% NCT04881760
- 76% vs 9% NCT04881760
- 59% vs 3% NCT04881760
- 72% vs 3% NCT04881760
- 27% vs 9% NCT04881760
- 25% vs 3% NCT04881760
- UBT251
- —Trial running · NCT07806851
Waist circumference, change (cm)
- retatrutide
- -19.6 vs -2.6−17 vs placeboNCT04881760
11 other results
- -14.3 vs -2.6 NCT04881760
- -18.5 vs -2.6 NCT04881760
- -18.5 vs -2.6 NCT04881760
- -13.7 vs -2.6 NCT04881760
- -15.0 vs -2.6 NCT04881760
- -14.6 vs -2.6 NCT04881760
- -14.9 vs -2.6 NCT04881760
- -10.3 vs -2.6 NCT04881760
- -12.6 vs -2.6 NCT04881760
- -6.5 vs -2.6 NCT04881760
- -5.4 vs -2.6 NCT04881760
- UBT251
- —Trial running · NCT07806851
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
UBT251: no structured comparison results are available for Obesity.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. retatrutide: 4 of 4 rows · UBT251: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | retatrutide |
|---|---|
| Dropout rate | 12.9%12 mg (2 mg) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 show 5 more results14.3%8 mg (2 mg) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 17.1%8 mg (4 mg) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 23.5%4 mg NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 21.2%4 mg (2 mg) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 13%1 mg NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 |
| Discontinued due to AEs | 3.2%12 mg (2 mg) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 show 5 more results2.9%8 mg (2 mg) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 2.9%8 mg (4 mg) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 0%4 mg NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 3%4 mg (2 mg) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 1.4%1 mg NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 |
| Serious AEs | 3.2%12 mg (2 mg) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 show 5 more results2.9%8 mg (2 mg) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 5.7%8 mg (4 mg) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 6.1%4 mg NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 0%4 mg (2 mg) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 4.3%1 mg NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 |
| Most frequent reported AEs | 12 mg (2 mg) nausea 45.2% (placebo 11.4%) decreased appetite 29% (placebo 8.6%) covid-19 24.2% (placebo 20%) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 show 5 more results8 mg (2 mg) diarrhoea 20% (placebo 11.4%) covid-19 17.1% (placebo 20%) nausea 17.1% (placebo 11.4%) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 8 mg (4 mg) nausea 60% (placebo 11.4%) covid-19 31.4% (placebo 20%) decreased appetite 31.4% (placebo 8.6%) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 4 mg nausea 36.4% (placebo 11.4%) decreased appetite 24.2% (placebo 8.6%) covid-19 18.2% (placebo 20%) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 4 mg (2 mg) decreased appetite 18.2% (placebo 8.6%) nausea 18.2% (placebo 11.4%) constipation 15.2% (placebo 2.9%) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 1 mg covid-19 18.8% (placebo 20%) nausea 14.5% (placebo 11.4%) decreased appetite 13% (placebo 8.6%) NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
retatrutide
show 14 more results
show 11 more results
show 11 more results
show 11 more results
show 11 more results
show 11 more results
show 11 more results
show 1 more result
Type 2 Diabetes
Shared mechanism: GLP-1/GIP/glucagon receptor (triple) · full Type 2 Diabetes pipeline
retatrutide
Developed by Eli Lilly
NCT04867785 · Phase 2 · completed
The study randomized 281 participants and used double blinding with both placebo and dulaglutide control arms. Its primary HbA1c endpoint was statistically significant versus placebo for the 4–12 mg retatrutide doses but not for 0.5 mg, producing a mixed dose-level result rather than a uniformly positive primary comparison.
Next expected readout: January 2027 · NCT06982859 (registry estimate)
Reported efficacy
Percent Change from Baseline in Body Weight (Baseline, Week 80); Change from Baseline in Apnea-Hypopnea Index (AHI) for GSA2 Subset (Baseline, Week 80): Primary endpoint, percent change in body weight from baseline to week 80 (treatment-regimen estimand): retatrutide 9 mg -16.8% and 12 mg -18.8% vs placebo -5.1%; treatment differences -11.8% (95% CI -13.7 to -9.8) and -13.8% (95% CI -15.8 to -11.8); p<0.0001 for both, met. Key secondary, 4 mg vs placebo: -11.9% vs -5.1% (difference -6.9%, 95% CI -8.7 to -5.1; p<0.0001). The registered AHI primary in the sleep apnea subset is not reported in the paper abstract. (met)
Result source: NCT05929079
UBT251
Developed by Novo Nordisk under a licence from United Bio-Technology (Hengqin)
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: September 2027 · NCT07659574 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | retatrutide | UBT251 |
|---|---|---|
| HbA1c, change | -2.0% vs -0.1%−2 vs placeboNCT0486778520 other results
| —Trial running · NCT07653477 |
| Body weight, change (kg) | -17.2 vs -3.3−13.9 vs placeboNCT0486778511 other results
| —Trial running · NCT07653477 |
| HbA1c below 7% | 80% vs 22%+58 vs placeboNCT0486778511 other results
| —Trial running · NCT07653477 |
| Fasting plasma glucose, change | —Not posted · NCT06354660 | —Trial running · NCT07653477 |
| 3-point MACE (% with event) | —Not posted · NCT06354660 | —Trial running · NCT07653477 |
HbA1c, change
- retatrutide
- -2.0% vs -0.1%−2 vs placeboNCT04867785
20 other results
- -2.0% vs -0.1% NCT04867785
- -1.9% vs -0.1% NCT04867785
- -1.4% vs -0.1% NCT04867785
- -1.3% vs -0.1% NCT04867785
- -0.4% vs -0.1% NCT04867785
- -2.2% vs -0.3% NCT04867785
- -2.0% vs -0.1% NCT04867785
- -2.1% vs -0.3% NCT04867785
- -1.9% vs -0.3% NCT04867785
- -2.0% vs -0.1% NCT04867785
- -1.9% vs -0.1% NCT04867785
- -1.3% vs -0.3% NCT04867785
- -1.5% vs -0.3% NCT04867785
- -1.4% vs -0.1% NCT04867785
- -1.3% vs -0.1% NCT04867785
- -0.5% vs -0.3% NCT04867785
- -0.4% vs -0.1% NCT04867785
- -1.9% vs -0.8% NCT06354660
- -2% vs -0.8% NCT06354660
- -1.7% vs -0.8% NCT06354660
- UBT251
- —Trial running · NCT07653477
Body weight, change (kg)
- retatrutide
- -17.2 vs -3.3−13.9 vs placeboNCT04867785
11 other results
- -12.8 vs -1.9 NCT04867785
- -16.5 vs -3.3 NCT04867785
- -16.1 vs -3.3 NCT04867785
- -12.0 vs -1.9 NCT04867785
- -13.9 vs -1.9 NCT04867785
- -7.3 vs -3.3 NCT04867785
- -10.4 vs -3.3 NCT04867785
- -6.3 vs -1.9 NCT04867785
- -8.6 vs -1.9 NCT04867785
- -3.3 vs -3.3 NCT04867785
- -2.4 vs -1.9 NCT04867785
- UBT251
- —Trial running · NCT07653477
HbA1c below 7%
- retatrutide
- 80% vs 22%+58 vs placeboNCT04867785
11 other results
- 86% vs 18% NCT04867785
- 82% vs 22% NCT04867785
- 78% vs 22% NCT04867785
- 88% vs 18% NCT04867785
- 78% vs 18% NCT04867785
- 61% vs 22% NCT04867785
- 59% vs 22% NCT04867785
- 53% vs 18% NCT04867785
- 66% vs 18% NCT04867785
- 37% vs 22% NCT04867785
- 32% vs 18% NCT04867785
- UBT251
- —Trial running · NCT07653477
Fasting plasma glucose, change
- retatrutide
- —Not posted · NCT06354660
- UBT251
- —Trial running · NCT07653477
3-point MACE (% with event)
- retatrutide
- —Not posted · NCT06354660
- UBT251
- —Trial running · NCT07653477
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
UBT251: no structured comparison results are available for Type 2 Diabetes.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. retatrutide: 4 of 4 rows · UBT251: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | retatrutide |
|---|---|
| Dropout rate | 23.9%12 mg (2 mg) NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2 show 5 more results3.8%8 mg (2 mg) NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2 8.3%8 mg (4 mg) NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2 17.4%4 mg (2 mg) NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2 12.5%4 mg (4 mg) NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2 12.8%0.5 mg NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2 |
| Discontinued due to AEs | 4.3%12 mg (2 mg) NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2 show 5 more results0%8 mg (2 mg) NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2 0%8 mg (4 mg) NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2 0%4 mg (2 mg) NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2 0%4 mg (4 mg) NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2 2.1%0.5 mg NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2 |
| Serious AEs | 4.3%12 mg (2 mg) NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2 show 5 more results7.7%8 mg (2 mg) NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2 4.2%8 mg (4 mg) NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2 4.3%4 mg (2 mg) NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2 8.3%4 mg (4 mg) NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2 6.4%0.5 mg NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2 |
| Most frequent reported AEs | 12 mg (2 mg) decreased appetite 19.6% (placebo 0%) nausea 19.6% (placebo 4.4%) diarrhoea 15.2% (placebo 4.4%) NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2 show 5 more results8 mg (2 mg) nausea 26.9% (placebo 4.4%) decreased appetite 19.2% (placebo 0%) diarrhoea 19.2% (placebo 4.4%) NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2 8 mg (4 mg) nausea 41.7% (placebo 4.4%) diarrhoea 29.2% (placebo 4.4%) decreased appetite 16.7% (placebo 0%) NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2 4 mg (2 mg) covid-19 13% (placebo 6.7%) constipation 8.7% (placebo 2.2%) cough 8.7% (placebo 0%) NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2 4 mg (4 mg) diarrhoea 25% (placebo 4.4%) nausea 25% (placebo 4.4%) decreased appetite 20.8% (placebo 0%) NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2 0.5 mg covid-19 10.6% (placebo 6.7%) constipation 6.4% (placebo 2.2%) decreased appetite 4.3% (placebo 0%) NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
retatrutide
show 20 more results
show 11 more results
show 5 more results
show 5 more results
show 11 more results
show 2 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: retatrutide's landscape · UBT251's landscape